TRP Natural Eyes sterile eye drops recalled due to lack of sterility assurance
AMMAN PHARMACEUTICAL INDUSTRIES is recalling TRP Natural Eyes Allergy Relief eye drops due to inability to assure sterility. The recalled lot includes 8,810 units distributed to accounts in Rhode Island and Colorado.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The source text does not report any illnesses, injuries, or hospitalizations. The hazard—lack of sterility assurance—represents a potential risk rather than confirmed harm. This FDA Class II recall without reported adverse effects meets the rubric criteria for a High severity score.
Plain-English summary
AMMAN PHARMACEUTICAL INDUSTRIES is recalling TRP Natural Eyes Allergy Relief PF sterile eye drops (10 mL, NDC 17312-097-19). The company cannot assure that the product meets required sterility standards for eye drops.
The recall affects 8,810 units from Lot FT001 (expiration date 07/24). The product was distributed to accounts in Rhode Island and Colorado.
If you have purchased this product, stop using it immediately. Contact your healthcare provider or pharmacist with any questions about this recall.
The recalled product
- Product
- TRP Natural Eyes, Allergy Relief PF, Sterile Eye Drops, Homeopathic 0.33 FL OZ (10 mL), Manufactured in Jordan, exclusively for TRP Company, Inc., 1575 Delucchi Lane, Reno, NV 89502, NDC: 17312-097-19.
- Manufacturer
- AMMAN PHARMACEUTICAL INDUSTRIES
- Category
- Drug — Eye Drops / Ophthalmic
- Hazard
- sterility-failure
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: FT001
- EXP: 07/24
Distribution
Distributed in 2 states:
- CO
- RI
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27